Skip to Content
Merck
  • Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro.

Combination of therapy with 5-fluorouracil and cisplatin with electroporation in human ovarian carcinoma model in vitro.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2014-07-01)
Jolanta Saczko, Iwona Kamińska, Malgorzata Kotulska, Julia Bar, Anna Choromańska, Nina Rembiałkowska, Katarzyna Bieżuńska-Kusiak, Joanna Rossowska, Danuta Nowakowska, Julita Kulbacka
ABSTRACT

High electric field, applied to plasma membrane, affects organization of the lipid molecules, generating transient hydrophilic electropores. The application of the cell membrane electroporation in combination with cytotoxic drugs could increase the drug transport into cells. This approach is known as electrochemotherapy (ECT). Our work shows new data concerning the influence of electrochemical reaction with cisplatin or with 5-fluorouracil (5-FU) on cancer ovarian cells resistant to standard therapy with cisplatin, in comparison to ECT effect on human primary fibroblasts. We investigated the effect of electroporation and electrochemotherapy with 5-FU and cisplatin on human ovarian clear-cell carcinoma cell line (OvBH-1) and epithelial ovarian carcinoma cell line (SKOV-3) - both resistant to cisplatin typically used in ovarian cancers. As control cells, human gingival fibroblasts (HGF's) from primary culture were used. Electropermeabilization efficiency was determined by FACS analysis with iodide propidium. Efficiency of electrochemotherapy was evaluated with viability assay. The cytotoxic effect was dependent on the electroporation parameters and on drug concentration. Electroporation alone only insignificantly decreased cells proliferation in OvBH-1 line; SKOV-3 line was more sensitive to the electrical field. Electrochemotherapy with cisplatin and 5-FU showed promising effects on both ovarian cell lines with recovery of normal cells revealed after 72 hours.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Supelco
5-Fluorouracil, analytical standard
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
Fluorouracil, European Pharmacopoeia (EP) Reference Standard
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
USP
Fluorouracil, United States Pharmacopeia (USP) Reference Standard
Supelco
Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
trans-Platinum(II)diammine dichloride
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Cisplatin, European Pharmacopoeia (EP) Reference Standard